biopharma-reporter.com
The sickle cell gene therapies developed by Bluebird Bio and Vertex will be the first to be offered under the new scheme.
19 days ago
biopharma-reporter.com
Biohaven’s myostatin inhibitor fails in phase 3 spinal muscular atrophy trial
28 days ago
chemistryworld.com
New antibiotic mechanism sees molecule infiltrate bacterial cells and destroy them from the inside
4 months ago
chemistryworld.com
Chemical approach is fast and flexible and could be an alternative o using protein engineering
over 1 year ago
chemistryworld.com
Informatic tools will help drug formulators understand particle behaviour in their final product
over 2 years ago
chemistryworld.com
Marker could be a simple answer to ensuring provenance of drugs
over 2 years ago
chemistryworld.com
Chemical looping process produces ultra-pure hydrogen from methane
about 3 years ago
chemistryworld.com
Soft lenses can correct red–green colour vision deficiency
almost 4 years ago